Tyrosine kinase inhibitors (TKIs) have vastly improved long-term outcomes for patients with
chronic myeloid leukemia (CML). After imatinib (a first-generation TKI), second-and third …

Abstract Purpose of Review Chronic myeloid leukemia (CML) is a disease that previously
signified a poor prognosis, but treatment options and outcomes have improved over the last …

Age and comorbidities are important factors to be considered in the selection of tyrosine
kinase inhibitors (TKIs) for first‐line treatment in patients with chronic myeloid leukemia in …

Background Imatinib, dasatinib, and nilotinib are tyrosine kinase inhibitors (TKIs) approved
in Italy for frontline treatment of chronic‐phase chronic myeloid leukemia (CP‐CML). The …

Simple Summary Many patients with chronic-phase chronic myeloid leukemia (CP-CML)
treated with a tyrosine kinase inhibitor (TKI) experience disease progression and switch to …

Here, we report real-world evidence on the safety and efficacy of nilotinib as a first-line
treatment in elderly patients with chronic phase CML, treated in 18 Italian centers. Sixty …

Guidelines for tyrosine kinase inhibitor (TKI)-treated chronic phase-chronic myeloid
leukemia (CML) management are essentially based on data from clinical research trials; …

Abstract Introduction Tyrosine kinase inhibitors (TKIs) have become the mainstay of
treatment for chronic myeloid leukaemia (CML), but cardiovascular (CV) risk and …

Background To evaluate the outcomes of first‐line imatinib versus nilotinib treatment for
chronic myeloid leukemia in the chronic phase (CML‐CP) in real‐world clinical practice …

Simple Summary Real world data represent a useful tool to obtain understanding into the
management of cancer disease in routine daily practice. To date, little is known on …